iHuman (IH)
NYSE:IH
Want to see IH full AI Analyst Report?
Top Page
iHuman
(NYSE:IH)
Select Model
Select Model
Rating:73Outperform
Price Target:
$2.00
▲(0.00% Upside)
Action:UpgradedDate:04/28/26
The score is driven by a strong financial foundation (minimal leverage) and very attractive valuation (low P/E). These positives are tempered by weakening operating trends (contracting revenue, margin compression) and mixed technicals with only modest near-term momentum.
Positive Factors
Balance sheet strength
Exceptionally low leverage and a large equity base give iHuman durable financial flexibility. This supports continued R&D, product investment, and shareholder returns through cycles, and reduces refinancing and solvency risk even if operating results soften over the next several quarters.
Negative Factors
Revenue decline & demographics
Declining revenues and a shrinking domestic birth cohort create a structural headwind to core preschool demand. Even with product diversification, a smaller native user base makes sustained top-line recovery harder and forces heavier reliance on international and ancillary product growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Exceptionally low leverage and a large equity base give iHuman durable financial flexibility. This supports continued R&D, product investment, and shareholder returns through cycles, and reduces refinancing and solvency risk even if operating results soften over the next several quarters.
Read all positive factors
iHuman (IH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$88.81M
Dividend Yield3.93%
Average Volume (3M)17.50K
Price to Earnings (P/E)1.6
Beta (1Y)0.38
Revenue Growth-12.43%
EPS Growth-1.57%
CountryUS
Employees723
SectorConsumer Defensive
Sector Strength42
IndustryEducation & Training Services
Share Statistics
EPS (TTM)0.04
Shares Outstanding22,544,950
10 Day Avg. Volume15,971
30 Day Avg. Volume17,505
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)0.15
Price to Sales (P/S)0.19
P/FCF Ratio3.34
Enterprise Value/Market Cap-11.46
Enterprise Value/Revenue-1.15
Enterprise Value/Gross Profit-1.70
Enterprise Value/Ebitda-13.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iHuman Business Overview & Revenue Model
Company Description
iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iH...
How the Company Makes Money
iHuman primarily makes money by monetizing its digital early childhood education products through paid access to content. Revenue is generated mainly from (1) subscriptions that provide ongoing access to its learning apps and content libraries, an...
iHuman Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
88
Very Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 882.69M | 785.03M | 922.20M | 1.02B | 985.52M | 944.72M |
| Gross Profit | 599.83M | 532.69M | 640.15M | 721.27M | 691.17M | 660.62M |
| EBITDA | 76.70M | 64.94M | 85.57M | 171.58M | 122.41M | -47.83M |
| Net Income | 110.03M | 92.80M | 98.59M | 180.91M | 109.82M | -37.05M |
Balance Sheet | ||||||
| Total Assets | 1.34B | 1.37B | 1.42B | 1.45B | 1.33B | 1.10B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 1.15B | 1.17B | 1.21B | 1.05B | 855.36M |
| Total Debt | 12.28M | 11.38M | 14.91M | 3.86M | 9.02M | 34.25M |
| Total Liabilities | 365.70M | 373.42M | 458.80M | 492.69M | 563.95M | 492.51M |
| Stockholders Equity | 969.39M | 995.80M | 960.85M | 957.80M | 769.45M | 608.37M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 45.15M | 51.10M | 165.61M | 1.25B | 5.93M |
| Operating Cash Flow | 0.00 | 49.92M | 58.55M | 172.12M | 1.29B | 38.21M |
| Investing Cash Flow | 0.00 | 39.45M | -52.76M | -6.51M | -225.03M | -31.95M |
| Financing Cash Flow | 0.00 | -54.56M | -102.28M | -9.45M | -47.66M | 410.00K |
iHuman Technical Analysis
Neutral
2.00
Price Trends
1.72
Negative
1.89
Negative
2.28
Negative
Market Momentum
-0.01
Negative
53.16
Neutral
50.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IH, the sentiment is Neutral. The current price of 2 is above the 20-day moving average (MA) of 1.63, above the 50-day MA of 1.72, and below the 200-day MA of 2.28, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.16 is Neutral, neither overbought nor oversold. The STOCH value of 50.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IH.
iHuman Risk Analysis
iHuman disclosed 87 risk factors in its most recent earnings report. iHuman reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We incurred net losses in the past, and we may not be able to remain profitable or increase profitability in the future. Q4, 2023
2.
If we are unable to manage our growth effectively, our business and prospects may be materially and adversely affected. Q4, 2023
3.
Uncertainties with respect to the legal system in mainland China, including uncertainties regarding the interpretation and enforcement of laws, regulations and policies of mainland China, could adversely affect us. As the legal system of mainland China is evolving, laws, regulations and rules in mainland China may change quickly with little advance notice, which may subject us to non-compliance due to unexpected changes to the laws, regulations and rules applicable to us. Q4, 2023
iHuman Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $88.81M | 1.63 | 11.71% | 3.93% | -12.43% | -1.57% | |
68 Neutral | $46.06M | 1.57 | 51.85% | ― | 1.58% | 8.26% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
55 Neutral | $157.69M | -0.19 | 69.84% | ― | 88.96% | -119.84% | |
52 Neutral | $65.03M | -0.56 | -709.20% | ― | -3.45% | -9.46% | |
41 Neutral | $52.83M | -1.05 | -37.31% | ― | 6.00% | 45.53% | |
40 Underperform | $1.27M | -0.62 | -19.03% | ― | 286.60% | -304.90% |
* Consumer Defensive Sector Average
IH
iHuman
1.74
-0.24
-12.17%
COE
China Online Education Group
27.94
11.10
65.91%
STG
Sunlands Online Education Group
3.37
-1.66
-32.95%
SKIL
Skillsoft
6.99
-12.29
-63.74%
KIDZ
Classover Holdings
1.09
-57.41
-98.14%
GNS
Genius Group Limited
0.30
-0.08
-21.32%
iHuman Corporate Events
iHuman Posts Lower 2025 Revenue but Maintains Profitability and Expands AI Learning Portfolio
Mar 31, 2026
On March 31, 2026, iHuman reported unaudited results for the fourth quarter and fiscal year ended December 31, 2025, showing revenue and user declines amid China’s shrinking newborn population and softer consumer spending. Fourth-quarter rev...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.